氟伏沙明早期治疗冠状病毒病19的前瞻性队列研究。
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.
作者信息
Seftel David, Boulware David R
机构信息
Golden Gate Fields Medical Clinic, Berkeley, California, USA.
Enable Biosciences Inc, South San Francisco, California, USA.
出版信息
Open Forum Infect Dis. 2021 Feb 1;8(2):ofab050. doi: 10.1093/ofid/ofab050. eCollection 2021 Feb.
Abstract
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.
摘要
我们报告了在大规模疫情背景下的一项前瞻性队列研究中使用氟伏沙明治疗冠状病毒病19（COVID-19）的真实世界经验。总体而言，65人选择接受氟伏沙明（每日两次，每次50毫克），48人拒绝。接受氟伏沙明治疗的患者住院率为0%（65人中0人），仅接受观察的患者住院率为12.5%（48人中6人）。在第14天时，接受氟伏沙明治疗的患者残留症状持续率为0%（65人中0人），仅接受观察的患者残留症状持续率为60%（48人中29人）。
相似文献
1
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.
Open Forum Infect Dis. 2021 Feb 1;8(2):ofab050. doi: 10.1093/ofid/ofab050. eCollection 2021 Feb.
2
Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before-after Analysis.
Microorganisms. 2023 Aug 12;11(8):2073. doi: 10.3390/microorganisms11082073.
3
Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study.
Front Pharmacol. 2022 Nov 30;13:1054644. doi: 10.3389/fphar.2022.1054644. eCollection 2022.
4
Characteristics and Outcomes of 241 Births to Women With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection at Five New York City Medical Centers.
Obstet Gynecol. 2020 Aug;136(2):273-282. doi: 10.1097/AOG.0000000000004025.
5
Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19).
Clin Infect Dis. 2020 Jul 28;71(15):799-806. doi: 10.1093/cid/ciaa351.
6
Rapid Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in Detention Facility, Louisiana, USA, May-June, 2020.
Emerg Infect Dis. 2021 Feb;27(2):421-429. doi: 10.3201/eid2702.204158. Epub 2021 Jan 4.
7
The Coronavirus Pandemic: What Does the Evidence Show?
J Nepal Health Res Counc. 2020 Apr 19;18(1):1-9. doi: 10.33314/jnhrc.v18i1.2596.
8
New York Inner City Hospital COVID-19 Experience and Current Data: Retrospective Analysis at the Epicenter of the American Coronavirus Outbreak.
J Med Internet Res. 2020 Sep 18;22(9):e20548. doi: 10.2196/20548.
9
Parental Coronavirus Disease 2019 Testing of Hospitalized Children: Rethinking Infection Control in a Pandemic.
J Pediatric Infect Dis Soc. 2020 Nov 10;9(5):564-565. doi: 10.1093/jpids/piaa103.
10
Pathogenesis-directed therapy of 2019 novel coronavirus disease.
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
引用本文的文献
1
Could antidepressants increase mood and immunity at the same time?
Front Psychiatry. 2025 Mar 12;16:1340179. doi: 10.3389/fpsyt.2025.1340179. eCollection 2025.
2
Protective effects of psychiatric medications against COVID-19 mortality before vaccines.
PLoS One. 2025 Feb 24;20(2):e0310438. doi: 10.1371/journal.pone.0310438. eCollection 2025.
3
Sertraline modulates hippocampal plasticity via sigma 1 receptors, cellular stress and neurosteroids.
Transl Psychiatry. 2024 Nov 21;14(1):474. doi: 10.1038/s41398-024-03185-3.
4
A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
Sci Rep. 2024 Jun 12;14(1):13462. doi: 10.1038/s41598-024-64260-9.
5
Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants.
Viruses. 2024 Mar 30;16(4):545. doi: 10.3390/v16040545.
6
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial.
EClinicalMedicine. 2024 Mar 14;70:102517. doi: 10.1016/j.eclinm.2024.102517. eCollection 2024 Apr.
7
Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19.
Int J Mol Sci. 2023 Dec 1;24(23):17039. doi: 10.3390/ijms242317039.
8
An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model.
Hum Genomics. 2023 Aug 29;17(1):80. doi: 10.1186/s40246-023-00521-4.
9
Medications Modulating the Acid Sphingomyelinase/Ceramide System and 28-Day Mortality among Patients with SARS-CoV-2: An Observational Study.
Pharmaceuticals (Basel). 2023 Aug 4;16(8):1107. doi: 10.3390/ph16081107.
10
Characterization of the cellular lipid composition during SARS-CoV-2 infection.
Anal Bioanal Chem. 2023 Sep;415(22):5269-5279. doi: 10.1007/s00216-023-04825-1. Epub 2023 Jul 13.
本文引用的文献
1
Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.
Circulation. 2021 Mar 9;143(10):1002-1013. doi: 10.1161/CIRCULATIONAHA.120.051718. Epub 2020 Dec 17.
2
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760.
3
Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis.
Sci Transl Med. 2019 Feb 6;11(478). doi: 10.1126/scitranslmed.aau5266.
Zotero 插件